As shown in Supplementary Table 1, RA patients achieving DAS-defined remission within 12 months of follow-up of CTLA4-Ig treatment did not differ in terms of baseline demographic and clinical parameters when compared to RA patients not reaching the same outcome, with no difference between early and established RA patients (data not shown). This evidence concerns the gene CTLA4 and rheumatoid arthritis.